PASSAGE BIO, INC. Impairment of Long-Lived Assets Held-for-use
PASSAGE BIO, INC. (PASG) reported Impairment of Long-Lived Assets Held-for-use of $3.37 million for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-09-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-09-03
- PASSAGE BIO, INC. impairment of long-lived assets held-for-use for the quarter ending 2024-12-31 was $0.00.
- PASSAGE BIO, INC. impairment of long-lived assets held-for-use for the quarter ending 2024-09-30 was $2.28M, a 28.78% decline year-over-year.
- PASSAGE BIO, INC. impairment of long-lived assets held-for-use for the quarter ending 2023-12-31 was $0.00.
- PASSAGE BIO, INC. impairment of long-lived assets held-for-use for the quarter ending 2023-09-30 was $3.20M.
- PASSAGE BIO, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $3.21M.
- PASSAGE BIO, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.37M S-4/A · filed 2026-09-03 | |||
| 2024-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $2.28M derived: sum of 2 quarters · filed 2026-09-03 | $2.28M S-4/A · filed 2026-09-03 | |
| 2024-09-30 | $2.28M 10-Q · filed 2024-11-13 | $2.28M 10-Q · filed 2024-11-13 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $3.20M derived: sum of 2 quarters · filed 2025-03-04 | $3.21M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $3.20M 10-Q · filed 2023-11-13 | $3.21M 10-Q · filed 2023-11-13 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | $0.00 derived: sum of 2 quarters · filed 2024-03-04 | $0.00 10-K · filed 2024-03-04 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |